Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Non-Current Assets (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Non-Current Assets for 6 consecutive years, with $30.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 67.92% to $30.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $154.3 million through Dec 2025, down 61.91% year-over-year, with the annual reading at $30.1 million for FY2025, 67.92% down from the prior year.
  • Non-Current Assets for Q4 2025 was $30.1 million at Caribou Biosciences, down from $39.5 million in the prior quarter.
  • The five-year high for Non-Current Assets was $113.5 million in Q4 2022, with the low at $12.9 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $72.6 million, with a median of $81.1 million recorded in 2023.
  • The sharpest move saw Non-Current Assets surged 611.69% in 2022, then crashed 72.18% in 2025.
  • Over 5 years, Non-Current Assets stood at $51.2 million in 2021, then surged by 121.87% to $113.5 million in 2022, then decreased by 17.75% to $93.4 million in 2023, then grew by 0.61% to $93.9 million in 2024, then crashed by 67.92% to $30.1 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $30.1 million, $39.5 million, and $28.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.